



Article

Gut Microbiota Ecological and Functional Modulation in Post-Stroke Recovery Patients: An Italian Study

Riccardo Marsiglia ¹, Chiara Marangelo ^{1,†}, Pamela Vernocchi ^{1,†}, Matteo Scanu ¹, Stefania Pane ²,
Alessandra Russo ², Eleonora Guanziroli ³, Federica Del Chierico ¹, Massimiliano Valeriani ^{4,5},
Franco Molteni ³ and Lorenza Putignani ^{6,*}

- ¹ Immunology, Rheumatology and Infectious Diseases Research Area, Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy; riccardo.marsiglia@opbg.net (R.M.); chiara.marangelo@opbg.net (C.M.); pamel.vernocchi@opbg.net (P.V.); matteo.scanu@opbg.net (M.S.); federica.delchierico@opbg.net (F.D.C.)
- ² Unit of Microbiomics, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy; stefania.pane@opbg.net (S.P.); alessandra.russo@opbg.net (A.R.)
- ³ Villa Beretta Rehabilitation Center, Valduce Hospital Como, 23845 Costa Masnaga, Italy; eleonora.guanziroli@gmail.com (E.G.); franco56.molteni@gmail.com (F.M.)
- ⁴ Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, 00165 Rome, Italy; massimiliano.valeriani@opbg.net
- ⁵ Center for Sensory Motor Interaction, Aalborg University, 9220 Aalborg, Denmark
- ⁶ Unit of Microbiomics and Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy
- * Correspondence: lorenza.putignani@opbg.net
- † These authors have contributed equally to this work.



Citation: Marsiglia, R.; Marangelo, C.; Vernocchi, P.; Scanu, M.; Pane, S.; Russo, A.; Guanziroli, E.; Del Chierico, F.; Valeriani, M.; Molteni, F.; et al. Gut Microbiota Ecological and Functional Modulation in Post-Stroke Recovery Patients: An Italian Study. *Microorganisms* **2024**, *12*, 37. <https://doi.org/10.3390/microorganisms12010037>

Academic Editors: Francesco Di Pierro and Zhi Liu

Received: 27 October 2023

Revised: 20 December 2023

Accepted: 22 December 2023

Published: 25 December 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Ischemic stroke (IS) can be caused by perturbations of the gut–brain axis. An imbalance in the gut microbiota (GM), or dysbiosis, may be linked to several IS risk factors and can influence the brain through the production of different metabolites, such as short-chain fatty acids (SCFAs), indole and derivatives. This study examines ecological changes in the GM and its metabolic activities after stroke. Fecal samples of 10 IS patients were compared to 21 healthy controls (CTRLs). GM ecological profiles were generated via 16S rRNA taxonomy as functional profiles using metabolomics analysis performed with a gas chromatograph coupled to a mass spectrometer (GC-MS). Additionally fecal zonulin, a marker of gut permeability, was measured using an enzyme-linked immuno assay (ELISA). Data were analyzed using univariate and multivariate statistical analyses and correlated with clinical features and biochemical variables using correlation and nonparametric tests. Metabolomic analyses, carried out on a subject subgroup, revealed a high concentration of fecal metabolites, such as SCFAs, in the GM of IS patients, which was corroborated by the enrichment of SCFA-producing bacterial genera such as *Bacteroides*, *Christensenellaceae*, *Alistipes* and *Akkermansia*. Conversely, indole and 3-methyl indole (skatole) decreased compared to a subset of six CTRLs. This study illustrates how IS might affect the gut microbial milieu and may suggest potential microbial and metabolic biomarkers of IS. Expanded populations of *Akkermansia* and enrichment of acetic acid could be considered potential disease phenotype signatures.

Keywords: ischemic stroke; gut–brain axis; gut microbiota ecology; SCFAs; tryptophan derivatives; fecal zonulin

1. Introduction

The gut–brain axis is a bidirectional communication system between the gut and the brain. In particular, it involves the central nervous system (CNS), the autonomous nervous system (ANS), the enteric nervous system (ENS) [1] and the gut microbiota (GM), the latter including all microorganisms (bacteria, fungi, archaea and viruses) that populate the human gastrointestinal (GI) tract [2]. The CNS and the GM have multiple avenues

of communication, including (i) neural (the vagal nerve); (ii) immune (cytokines) and (iii) metabolic (short-chain fatty acids, SCFAs) pathways. Perturbation of this axis can be involved in neurodegenerative disorders [3]. In particular, “top-down” signaling, from CNS to the gut, can influence the ANS directly, via the sympathetic and parasympathetic systems, or indirectly, through the modulation of the enteric nervous system [4]. These nervous signals can influence motility, permeability, microbiota composition and other intestinal functions [5]. Conversely, the GM can influence the brain through “bottom-up” signaling. Neurotransmitters and signaling molecules, such as SCFAs, γ -amino-butyric acid, tryptophan derivatives, catecholamines and bile acid metabolites, can interact both with receptors in the gut wall and the ENS to communicate to the brain through vagal afferents [6,7]. The GM is closely related to human health and is composed of a multitude of different bacterial species, mostly belonging to six main phyla, i.e., Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia [8]. Under normal circumstances, the GM performs many crucial physiological functions, such as the maintenance of gut integrity [9], the production of SCFAs via fermentation of complex polysaccharides, the biosynthesis of essential amino acids and vitamins [10], and protection against pathogens by regulating host immunity [11]. On the other hand, an imbalance within the GM (i.e., dysbiosis) is related to numerous GI and metabolic diseases, including diabetes, dyslipidemia and obesity [12], which along with hypertension and atherosclerosis represent important risk factors for ischemic stroke (IS).

IS occurs when an obstruction leads to substantial decrease in blood flow to the brain [13]. Furthermore, IS can lead to alterations in the composition of the GM and its functions, and, conversely, GM alterations and changes in GM-derived metabolites have been associated with IS risk [14]. Several studies have linked patient prognosis following IS with GM dysbiosis [15] and altered SCFA production, which in turn have numerous homeostatic and anti-inflammatory effects related to GM biochemistry [16].

IS can occur at any age or stage of life. While the incidence of pediatric stroke is considerably lower than it is in adults, the neurological consequences [17] showing an impact on life quality and on the health care service is significantly higher following pediatric stroke [18].

The aim of this study was to examine changes in GM taxonomy and its activity in patients after a stroke event in order to identify biomarkers of disease and patient prognosis. Furthermore, this study aims to generate a disease-related GM model that could be transferred to pediatric populations.

2. Materials and Methods

2.1. Study Participants and Clinical Data

Ten patients with ischemic stroke (IS) aged 54–81 years (median, 70.5 years \pm IQR 14) of whom there were 6 males and 4 females, were recruited at the Villa Beretta Rehabilitation Center, Valduce Hospital, Costa Masnaga, Lecco, Italy, between January and December 2021. Twenty-one age-matched healthy subjects (median, 66.0 years \pm IQR 9.0), belonging to an epidemiological survey executed at the Human Microbiome Unit of Bambino Gesù Children’s Hospital in Rome (BBMRI Human Micro-biome Biobank, OPBG) were considered to constitute a sample and digital biobank of reference controls (CTRLs).

The majority of patients presented risk factors for ischemic stroke, including hypertension, diabetes, dyslipidemia and obesity (Table S1). They received routine pharmacotherapy for controlling comorbidities such as amlodipine and metformin. Exclusion criteria for the study were: hemorrhagic stroke or hemorrhagic infarction, probiotics and antibiotics administration at least one month prior to sample collection, and GI, oncological or neurodegenerative diseases. The participants’ metadata, including clinical assessment to evaluate lower limb function and blood biochemical parameters (BBP) (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), triglycerides, cholesterol, glucose, albumin and bilirubin), were evaluated at T_0 (beginning of rehabilitation period) and at T_1 (6 weeks later) at the Rehabilitation Center. Anamnestic

variables (age, BMI) were recorded at T_0 . After the stroke event, a clinical evaluation based on the International Classification of Functioning, Disability and Health (ICF) [19] was performed at T_0 and T_1 time points on both the affected and nonaffected sides, with different assays such as: the Box and Block test (BBT) to determine the number of blocks moved from one side to the other by the arm [20]; the Action Research Arm test (ARAT) to evaluate arm and hand functions [21]; the Motricity Index test (MI_TOT) to estimate lower extremities' strength [22] and the 10-Meter Walking test (10 MWT) to evaluate walking speed over a 10 m distance [23].

In the current study, considering the small sample size, only the continuous variable MI_TOT was evaluated to assay the motricity on the affected side.

2.2. Ethics Statement

The study was approved by the Villa Beretta Ethics Committee for patients with ischemic stroke (protocol v.1.2 10/11/2020) and by the OPBG Ethics Committee for healthy subjects' (1113_OPBG_2016) cohorts. Written informed consent was obtained from all participants.

2.3. Fecal Sample Collection

Ten fecal samples from IS patients were collected at T_0 and T_1 and immediately frozen at $-20\text{ }^{\circ}\text{C}$ at the Villa Beretta Rehabilitation Center, Valduce Hospital, and then delivered to the Human Microbiome Unit of Bambino Gesù Children's Hospital in Rome, where they were stored at $-80\text{ }^{\circ}\text{C}$ until metataxonomy and metabolomics analyses and gut permeability assay were performed. Fecal samples from the age-matched CTRLs were available as aliquots at $-80\text{ }^{\circ}\text{C}$ at the OPBG BBMRI Biobank. Further ecological profiles were provided for the 10 IS patients and 21 CTRLs, the latter including 15/21 digital profiles already available as biobank content and 6/21 newly produced.

2.4. 16S rRNA Targeted Metataxonomy Analysis

The general workflow included DNA extraction using the QIAmp Fast DNA Stool mini kit from Qiagen, Hilden, Germany and amplification and sequencing of the variable region V3–V4 from the 16S rRNA gene, according to 16S Metagenomic Sequencing Library preparation protocol (Illumina, San Diego, CA, USA). The raw reads were analyzed by Quantitative Insights into Microbial Ecology software (QIIME 2 v2023.2) [24]. The QIIME2 plugin for DADA2 was used for quality control, denoising, chimera removal, trimming and construction of an amplicon sequence Variant (ASV) table.

The taxonomic analysis was performed using a naïve Bayes model pretrained on database Greengenes (v13.8, August 2013, <https://greengenes.secondgenome.com/>) through the QIIME2 plugin q2-features classifiers. Sequencing data associated with this study were uploaded to the NCBI bioproject database: PRJNA1030992 (IS patients), PRJNA996768 and PRJNA531579 (CTRLs).

2.5. Gas Chromatography Coupled to Mass Spectrometry (GC-MS) Metabolomics Analysis

Overall, 10 patient samples and the subset of available CTRL biobank samples (i.e., 6/21), were processed for indole, 3-methyl-indole (skatole) and SCFAs determinations.

Hence, SCFAs, indole and skatole concentrations were estimated by Gas Chromatograph (GC) 7890 A (Agilent Technologies, Santa Clara, CA, USA) coupled to a mass spectrometer (MS) 5977 (Agilent Technologies, Santa Clara, CA, USA) in electron impact mode (ionization voltage of 70 eV) equipped with a DB-HeavyWAX (60 m \times 0.250 mm \times 0.25 μm) capillary column Agilent Technologies. In particular:

- An aqueous stock standard solution was prepared from chemical reagents of acetic acid (99%), propanoic acid (99%) and butanoic acid (99%) purchased by Merck (Darmstadt, Germany) with a concentration of 200 mm for each acid. All the stock standard solutions were stored at $-20\text{ }^{\circ}\text{C}$ until used.

- For SCFAs analysis, fecal samples (250 mg) were added to 1.25 mL of H₂O and homogenized in a shaker for 3 min. The samples were then acidified with HCl (3 M) to a pH of 2–3. Finally, they were centrifuged at 5000× g at 4 °C for 10 min. After centrifugation 1 mL of supernatant was centrifuged at 15,000× g at 4 °C for 15 min. The supernatant was transferred and basified at pH 6 with NaOH (5 M), after which hexanoic acid (final concentration of 0.4 mg/mL) was added as an internal standard before sample screening. The samples were then filtered through 0.45 µm and 0.22 µm filters. Finally, 1 µL of each sample was injected into GC-MS. The temperature program was: 50 °C for 2 min, a temperature increase of 10 °C per min at 70 °C, 3 °C per min at 85 °C, 5 °C per min at 110 °C, 15 °C per min at 200 °C, 20 °C per min at 230 °C, 10 °C per min at 240 °C, then 240 °C for 5 min, according to the adapted *in house* procedures performed by Zhao et al. [25]. The method was validated by *in house* procedures according to European Medicines Agency (EMA) and FDA guidelines [26,27] on bioanalytical method validation. The linearity of the calibration curve for each SCFA was assessed by the calculation of the coefficient of determination (R²). Validation was based on coefficient of variability (CV) of inter- and intraday reproducibility (%), limit of detection (LOD), limit of quantification (LOQ) and % of recovery.
- For indole and skatole determinations, fecal samples (100–500 mg) were managed and analyzed as previously described by Vernocchi et al. [28] using GC-MS coupled to solid-phase microextraction (SPME).

Compound identification was confirmed by injection of pure standards and a comparison of the retention time and corresponding MS spectra. Moreover, corroboration of the identification of all molecules was conducted by searching mass spectra in the National Institute of Standards and Technology (NIST, Rockville, MD, version 2d, build 26 April 2005) library and in the literature. Chromatograms were integrated and the quantitative data, expressed in mg/kg, were obtained by interpolation of the relative areas and the area of the internal standard.

2.6. Fecal Markers of Intestinal Inflammation and Permeability (Zonulin)

Zonulin was detected using an ELISA kit (IDK Zonulin ELISA for the *in vitro* determination of zonulin family peptides, ZFP, in stool, Immunodiagnostik AG, Bensheim, Germany) according to the manufacturer's protocol using 15 mg of patient stool sample. Briefly, a biotinylated zonulin tracer was added to samples, standards, and controls. The treated samples, standards, and controls were incubated in microtiter plates coated with anti-zonulin polyclonal antibodies for one hour. Samples were then washed five times in 250 µL wash buffer, and the remaining liquid was absorbed. The biotinylated zonulin tracer is associated with peroxidase and can be found in streptavidin (100 µL), which was subsequently added to each well. The microplate was incubated, washed, and drained as described previously. The samples were then incubated with 100 µL substrate solution for 15 min, after which the reaction interrupted with an acidic stop solution. The absorption was determined immediately at 450 nm against a reference wave of 620 nm using an Infinite® F50 compact ELISA absorbance microplate reader (TECAN, Männedorf, Switzerland). The quantitative data were represented by zonulin concentrations in ng/mL.

2.7. Statistical Analyses Processing

Firstly, longitudinal IS GM ecology, compared to CTRLs, was investigated at T₀ and T₁. Removal of unassigned ASVs and rarefaction of samples was performed. ASV table was filtered out, retaining the ASVs present in at least the 25% of the total samples. Moreover, a filter based on ASVs with relative abundance >1% was applied. A filtered matrix was selected for applying statistical analysis. The GM composition of patient and CTRL groups were analyzed and α and β diversity were performed by R “Phyloseq” package. The α diversity was calculated with R, using Shannon, Simpson and Chao1 indexes and Kruskal–Wallis and Mann–Whitney tests were applied for group comparisons. Principal coordinate analyses (PCoA) plots were constructed to illustrate the β-diversity algorithm based on

the Bray–Curtis index. To test the association between the covariates and β -diversity algorithms, permutational analysis of variance (PERMANOVA) was used [29]. Targeted-metagenomics data were analyzed using supervised partial least-squares-discriminant analysis (PLS-DA) performed with the R “mixOmics” package for Bioconductor [30]. For metataxonomy (ASVs), metabolomic (SCFAs) and fecal marker (zonulin) results, the data normality distribution was evaluated using the Shapiro–Wilk test and non-parametric (Mann–Whitney U-test and Kruskal–Wallis, comparing population medians) and parametric test (*t*-test comparing population means) were used. Statistical significance was assessed at p -value ≤ 0.05 corrected by Benjamini–Hochberg FDR procedure [31]. The relative abundance of taxa in IS patients and CTRLs was represented with bar plot (R “ggplot2” package). The functional analysis was performed using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt2) [32]. Linear discriminant analysis effect size (LEfSe) was used to reveal the direction of pathways statistically significant between IS patients and CTRLs. To obtain KEGG description, the online database <https://www.genome.jp/kegg/ko.html> was used [33].

To correlate microbial taxa and SCFAs, Spearman correlation coefficients were exploited and corresponding p -values (corr.test function in the R “psych” package) were represented by a heatmap (R “pheatmap” package) [34].

Moreover, to evaluate associations between pairs of variables (i.e., metabolites, ASVs abundances, BBP and clinical variables), linear regression models and multivariable Pearson correlation tests were performed for continuous variables such as MI_TOT and BBP.

3. Results

3.1. Subject Characteristics, Anamnestic and Clinical Features

In this study, the 10 recruited IS patients were clinically evaluated. No significant differences between IS patient and CTRL sample groups were observed in age distribution (p -value = 0.095, non-parametric Mann–Whitney test). The majority of the IS patients presented risk factors for IS including hypertension ($n = 8/10$), diabetes ($n = 2/10$) and dyslipidemia ($n = 6/10$). Furthermore, at T_0 , obese ($n = 2/10$) and overweight ($n = 5/10$) IS patients showed higher values of triglycerides, glucose and cholesterol compared to those with normal weight ($n = 3/10$) (Table S1).

Neurological features regarding the evaluation of functional movement in IS patients (MI_TOT; BB; ARAT; 10 MWT) were reported in Table S1. Of note, most IS patients ($n = 7/10$) at T_0 were not able to walk and thus had a score of 10 MTW, whereas all patients started walking at T_1 .

Considering the BBT on the affected side, 5 out of 10 IS patients were able to move more than 23 blocks at T_0 , which increased to 8/10 at T_1 . Regarding ARAT of the affected side, 8 out of 10 IS patients showed score of <57 at T_0 , while the other 2 did not show any deficit. At T_1 , 3 out of 10 IS patients showed score of <57 , while the other 7 showed the maximum score value of 57 (Table S1).

The MI_TOT, evaluated on the only affected side, showed an increase at T_1 (mean $69.8 \pm \text{SD } 29.9$) compared to T_0 (mean $46.5 \pm \text{SD } 29.4$).

3.2. Gut Microbiota Metaxonomy

A total of 4428 sequences of 16S rRNA gene amplicons were obtained with a frequency average of 41,641 amplicons/sample and an average length of 406 nt (nucleotide) (calculated after primer removal). The GM composition of IS patients at T_0 and T_1 and CTRLs was analyzed by ecological analysis.

Firstly, the α diversity was performed in order to evaluate the GM diversity between CTRLs and IS patient groups. The α diversity, performed via Chao1 index, showed a significant difference between CTRLs and IS patients; in particular, CTRLs GM showed higher values of diversity, when compared to IS_GM, either at T_0 and T_1 (p -value = 0.042 and p -value = 0.038, respectively; Figure 1A). On the contrary, no statistically significant

differences between patients and CTRLs, evaluated using Shannon and Simpson indexes, was observed.




Figure 1. GM ecological analysis. (A) Alpha-diversity of IS T₀ and IS T₁ cohorts and CTRLs based on Chao-1 index (*p*-value by pairwise comparisons using the Mann-Whitney test). (B) Principal coordinate analysis (PCoA) plots shows beta diversity of IS T₀ and IS T₁ cohorts and CTRLs performed using the Bray-Curtis index. Legend: IS_T₀: IS patients at T₀; IS_T₁: IS patients at T₁; CTRL: controls subjects.

Moreover, β diversity, performed by Bray–Curtis distance, showed IS patients (T₀ and T₁), grouped into two overlapping clusters, separated from CTRLs (*p*-value = 0.001, PERMANOVA; Figure 1B).

Also, the PLS-DA score plot (Figure 2A) showed clear group separation between CTRLs and IS patients. The loadings plot (Figure 2B) revealed that Coriobacteriaceae, Mogibacteriaceae, *Dorea* and Clostridiales discriminated the CTRLs, while *Phascolarctobacterium*, Christensenellaceae, *Sutterella* and *Alistipes* were associated with the IS patient group.

Consistent with previous findings, the GMs of both patients and CTRLs were composed of five main phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Verrucomicrobia. Particularly, Firmicutes and Bacteroidetes were the predominant phyla of both IS patients and CTRLs. However, the Verrucomicrobia and Proteobacteria phyla were significantly less abundant in CTRLs, while Actinobacteria phylum was more abundant in CTRLs than IS patients. Specifically, IS patients at T₁ showed a significant increment (*p*-value FDR \leq 0.01) of Verrucomicrobia compared to patients at T₀ (Figure 3A).




Figure 2. (A) Score plot of PLS-DA; (B) loading plot of all ASVs on Component 1. Legend: IS_T0: IS patients at T0; IS_T1: IS patients at T1; CTRL: controls subjects.

The analysis of ASVs distribution at family level (L5) showed a significant higher abundance of Clostridiaceae (p -value FDR ≤ 0.05), Ruminococcaceae (p -value FDR ≤ 0.05) and Coriobacteriaceae (p -value FDR ≤ 0.01) in CTRLs compared to IS patients at both time points, whereas Verrucomicrobiaceae (p -value FDR ≤ 0.01) and Bacteroidaceae (p -value FDR ≤ 0.01) were significantly increased in IS patients cohort, specifically at T1 (Figure 3B). Conversely, Streptococcaceae (p -value FDR ≤ 0.01), Rikenellaceae (p -value FDR ≤ 0.01) and Enterobacteriaceae (p -value FDR ≤ 0.01) were significantly reduced in CTRLs compared to IS patients (Figure 3B).




Figure 3. ASV distributions at L2 (A); L5 (B); and L6 (C) of the GM profiling of CTRL, IS_T0 and IS_T1. At L5 and L6 ASV filtered by statistical significance based on the Kruskal–Wallis test. *** p -value $FDR \leq 0.001$; ** p -value $FDR \leq 0.01$; * p -value $FDR \leq 0.05$. Legend: IS_T0: IS patients at T0; IS_T1: IS patients at T1; CTRL: controls subjects.

At the genus level (L6), *Anaerostipes* (p -value FDR ≤ 0.05) and Clostridiales (p -value FDR ≤ 0.05) were significantly increased in the CTRLs (Figure 3C), while *Phascolarctobacterium* (p -value FDR ≤ 0.01), *Alistipes* (p -value FDR ≤ 0.001), Christensenellaceae (p -value FDR ≤ 0.01) and Sutterella (p -value FDR ≤ 0.001) were enriched in the GM of IS patients (Figure 3C). Moreover, *Akkermansia* (p -value FDR ≤ 0.05) and *Bacteroides* (p -value FDR ≤ 0.01) showed a significant decrement in the CTRLs compared to IS patients at both time points and these genera were more abundant in IS patients at T₁ compared to IS_T₀ (Table S2). Furthermore, there were not statistically significant ASVs differences comparing IS patients at T₁ and T₀ time point (Table S2).

Focusing on the IS patients' and CTRLs' GM ecology comparison at T₀, the LEfSE analysis corroborated the ASVs associated to the IS disease through the longitudinal time points, namely *Bacteroides*, *Akkermansia*, *Alistipes*, Christensenellaceae (Figure S1). Moreover, the PICRUSt, predicted the main IS- and CTRL-related functional pathways. The LEfSe analysis showed 50 pathways differentially expressed (p -value ≤ 0.05). In particular, 33/50 were associated to IS, including lipopolysaccharide (LPS) biosynthesis and butanoate metabolism, while 17/50 to CTRLs (Figure S1B).

3.3. Gut Microbiota Metabolome Characterization

The GM metabolome composition (SCFAs, indole and skatole) was analyzed on the subset of 20 IS patients at T₀ and T₁ (median, 70.5 years \pm IQR 14) and 6 CTRLs (i.e., 6/21, median, 44.5 years \pm IQR 30.25) by GC-MS/SPME analysis (Table S3). Particularly, acetic acid showed highest values (Figure 4A), followed by butanoic (Figure 4B) and propanoic acid (Figure 4C).




Figure 4. Distribution of SCFAs (Acetic Acid in panel A; Butanoic Acid in panel B; Propanoic Acid in panel C) in CTRL, IS patients at T₀, IS patients at T₁ (Kruskal–Wallis test, * p -value ≤ 0.05 , ** p -value ≤ 0.01). IS_T₀: IS patients at T₀; IS_T₁: IS patients at T₁; CTRL: controls subjects.

In addition, by considering the comparison between the IS patients and CTRLs, acetic acid and butanoic acid were significantly increased in the IS GM patients at T₀ and T₁ compared to the CTRLs, while propanoic acid only showed significant differences at T₁ compared to the CTRLs.

Moreover, skatole concentrations were under the Limit of Quantification (LOQ) for 5/10 IS_T₀ and 6/10 IS_T₁ patients, while the others showed lower levels compared to CTRLs (Table S3).

Indole was only detected in the CTRL group (mean 287.2 mg/kg), while its concentration was under the LOQ in the IS patients (Table S3).

3.4. Fecal Markers of Intestinal Permeability (Zonulin)

Regarding zonulin concentrations, higher values were observed for the IS patients at T₁ compared to the IS patients at T₀ (p -value ≤ 0.05) (Figure S2).

3.5. Correlation Analysis of Omics Data, Clinical Features and BBP

The Spearman correlation between SCFAs, zonulin and ASVs, showed in the heatmap (Figure 5), highlighted statistically significant (p -value ≤ 0.05) positive correlation, particularly between *Blautia* with acetic and butanoic acid; *Ruminococcus* (Ruminococcaceae) with acetic acid; *Streptococcus* with acetic, propanoic and butanoic acid; *Lachnospira* with butanoic and propanoic acid; *Catenibacterium* with butanoic acid. Furthermore, there were statistically significant (p -value ≤ 0.05) negative correlations, in particular between *Methanobrevibacter* with acetic and propanoic acid; *Desulfovibrio*, *Parabacteroides* and *Succinivibrio* with zonulin (Figure 5).




Figure 5. Correlation's heatmap between ASVs, SCFAs, and zonulin performed using Ward's clustering method and Euclidean distance. * p -value ≤ 0.05 ; ** p -value ≤ 0.01 , *** p -value ≤ 0.001 .

Moreover, the correlation between motricity index (MI_TOT), BBP (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), triglycerides, cholesterol, glucose, albumin and bilirubin) with the ASV, SCFAs and zonulin concentrations of the 10 IS patients at different time points were considered.

The correlation analysis between MI_TOT at time T₀ and ASVs, SCFAs showed significant negative correlations with Christensenellaceae ($R = -0.66$, p -value = 0.038) and

with acetic acid ($R = -0.76$, p -value = 0.01) (Figure S3A). At time T_1 MI_TOT was negatively correlated with *Bacteroides* ($R = -0.73$, p -value = 0.018), *Clostridium* (Lachnospiraceae) ($R = -0.71$, p -value = 0.022) (Figure S3 (B1,B2)), and no significant (p -value > 0.05) correlations with any SCFA.

In addition, the correlation analysis between BBP at T_0 and T_1 and ASVs (at L6) was performed (Table S4). Particularly, by considering IS patients at T_0 high positive and significant (p -value ≤ 0.05) correlations were observed: tryglicerides with *Akkermansia* and *Streptococcus*; AST with *Succinivibrio* and *Prevotella*; GGT with *Coprococcus*, *Alistipes*, *Butyricimonas* and *Sutterella*; glucose and albumin with *Streptococcus*. Conversely, negative and significant (p -value ≤ 0.05) correlations were observed as follows: ALT with Christensellaceae; tryglicerides with *Faecalibacterium*; glucose with *Megasphaera* (Table S4).

Considering clinical data of IS at T_1 , high positive and significant (p -value ≤ 0.05) correlations were observed between AST and *Akkermansia*; cholesterol and *Ruminococcus* (Ruminococcaceae); glucose and *Alistipes*; bilirubin with *Anaerostipes*, Erysipelotrichaceae, *Eubacterium*, *Prevotella* and Enterobacteriaceae. On the other hand, ALT was negatively correlated with *Ruminococcus* (Ruminococcaceae) and *Prevotella* and there was negative significant (p -value ≤ 0.05) correlation between tryglicerides and Christensenellaceae (Table S4). By performing the correlation analysis between BBP, SCFAs and zonulin related to IS patients at T_0 , positive correlations (p -value ≤ 0.05) were observed between zonulin with triglycerides and albumin (Table 1).

Table 1. Correlation coefficients between SCFAs, and zonulin with BBP related to IS patients at time T_0 .

Blood Biochemical Parameters (BBP)	Acetic Acid	Propanoic Acid	Butanoic Acid	Total SCFA	Zonulin
ALT (U/L)	−0.396	−0.463	−0.492	−0.543	0.402
AST (mU/ mL)	0.036	−0.064	−0.324	−0.19	−0.006
GGT (U/L)	−0.257	0.337	−0.238	−0.204	−0.198
Tryglicerides (mg/dL)	0.028	0.387	0.018	0.083	0.738 *
Cholesterol (mg/dL)	0.186	0.614	0.608	0.545	0.359
Glucose (mg/dL)	−0.152	0.556	0.033	0.04	0.568
Albumin (g/mL)	0.251	0.412	0.442	0.441	0.73 *
Bilirubin (mg/dL)	−0.516	−0.168	−0.255	−0.406	0.125

* Statistically significant (p -value ≤ 0.05).

The BBP values in IS patients at T_1 did not significantly correlate with SCFAs and zonulin (Table S5).

4. Discussion

The aim of this study was to investigate the bidirectional communication along the gut–brain axis in IS patients. Dysfunction of the gut–brain axis, induced by dysbiosis, and GM variations are related to stroke risk factors such as obesity and atherosclerosis [35,36] and seem to be involved in the formation of atherosclerotic plaques [37]. Furthermore, some evidence suggests that stroke itself noticeably affects changes in the gut microbiota, and that these alterations, that could be linked to an increase in inflammation in different neurological diseases, in turn could influence stroke outcome [38].

Principally, it has been possible to observe GM taxonomy changes in IS patients after stroke compared to CTRLs, in particular with a decrease in Ruminococcaceae and Clostridiales (Clostridiaceae) and an increase in *Akkermansia*, *Bacteroides* and *Alistipes*, Christensenellaceae and *Sutterella*, recognized to be SCFA-producing bacteria, corroborated also by previous studies [39].

These microbes can act as pro- or anti-inflammatory agents, depending on different conditions. Several studies observed that these bacteria could ameliorate the symptoms of neuropsychiatric disorders by restoring the GM, mucosal barrier integrity and by modulating neuroinflammation [40–42]. Conversely, Bonnechère et al. showed that the genus *Akkermansia* was consistently enriched in the GMs of patients affected by neurological

disorders, such as Parkinson's disease, multiple sclerosis and stroke [38]. Moreover, *Akkermansia* has been also associated with diabetes and cardiovascular diseases, both common comorbidities of neurological disorders [38].

Furthermore, consistently with our results, Chen et al. [43] reported ischemic stroke triggering gut microbial alteration through enriching pathogens and opportunistic microorganisms such as SCFAs producers *Bacteroides* and *Alistipes* [44].

However, also an increment of *Bacteroides* and *Alistipes* has been observed in Alzheimer's and Parkinson's diseases, suggesting these genera as microbial potential indicators of CNS disorders [38,45].

In addition, previous studies have found an enrichment of Christensenellaceae, another SCFAs-producing genus, [46,47] in the gut of ischemic stroke patients [48].

Furthermore, *Sutterella*, an acetate producer, could be involved in neurodevelopmental disorders such as autism spectrum disorder (ASD) [49,50], gastrointestinal (GI) diseases, including inflammatory bowel disease (IBD) and coeliac disease (CD), and their comorbidities, such as cardiovascular disease and obesity [51,52].

After stroke, the noradrenaline release and the disruption of the axis between the gut and the vagus nerve may trigger GM modifications in injured patients, typically with a decrease in Ruminococcaceae [53–55], may be involved in the regulation of the immune system [56], as the same trend also occurred in IS patients in our study. Many studies examining changes in the GM of stroke patients have found a decrease in Clostridiaceae compared to health controls, consistent with these results. This reduction may be associated with an elevated inflammatory response or with infections post stroke, possibly related to serious brain injury and poor stroke outcome [14].

Moreover, following the ecological characterization of our cohort in which several SCFAs-producing bacteria were found, the prediction of functional profile showed several metabolic pathways associated with IS patients as butanoate metabolism and LPS biosynthesis pathways. Our results were in agreement with other evidence showing LPS synthesis significantly enriched in IS subjects [57]; also, Jia et al. [58] reported butanoate metabolism's upregulation in high-risk IS subjects as observed in murine model.

Consistently with these findings, a higher SCFAs fecal concentration, specifically acetic, propionic and butanoic acid was observed in our patients' cohort after stroke event compared to CTRLs. SCFAs, as is well known, may have both beneficial or detrimental effects, in relation to their concentration, in different neurological diseases, as they are involved in gut–brain axis communication [51]. After stroke, SCFAs could have a role in the immune system, in particular on microglial activation and on T-cell recruitment to the infarcted brain [59]. Indeed, SCFAs have been shown to readily cross the blood–brain barrier and could induce beneficial therapeutic effects during the recovery period [60]. On the other hand, when present at high concentrations, as in our study, SCFAs may behave as neurotoxins passing through the mucosa layer and cell membranes where they could exert toxic effects [61] and may lead to neutrophil accumulation and exacerbation of inflammatory processes [62].

Moreover, high concentrations of acetic acid, the most expressed of all the SCFAs in this patients cohort, may be related to GM alterations as a consequence of acute brain injury [63]. Hence, several studies identified a dysregulation of metabolic activity of the GM in patients after stroke [12], as reported by Xu et al. [64]. This study found that cerebral ischemia could rapidly induce GM disorders and stimulate excessive nitrate production, which in turn could affect the anaerobic fermentation of carbohydrate degradation, leading to an increase in acetate production [65].

Previous evidences have found a progressive reduction in fecal SCFAs in elderly people [66,67], though this study revealed an increase in butanoic acid in elderly patients without any significant gut microbial changes. This could probably be associated with the stroke event, and a consequent increase in pro-inflammatory commensals to the detriment of beneficial microbes [68], but the potential clinical consequences remain to be fully elucidated due to high degree of variability of the human GM [68].

GM alterations are also known to be associated to motor functions and general disability level [69] as a consequence of a stroke event. In this study, elevated levels of SCFAs were detected in IS patients with limited motricity, which could be correlated with a decrease in intestinal contractile activity caused by inflammation secondary to the injury [70].

Zonulin, an indirect intestinal inflammatory biomarker, could also be associated with stroke and chronic inflammation [71]. Moreover, other studies have shown increased levels of zonulin in older adults with frailty [72]. In this work, there were significant differences in fecal zonulin concentrations between IS patients at different time points, as also observed by Zheng et al. [73], which probably reflects an intestinal or systemic inflammatory condition. In addition, the role of tryptophan derivatives, such as indole and skatole, emerged as important intermediaries in the microbiota–gut–brain axis communication [74,75]. After stroke, several immunoregulatory pathways, such as the aryl hydrocarbon receptor (AHR) pathway, become activated, which is dependent on a dynamic balance between host-derived and GM-derived ligands (tryptophan derivatives as kynurenine and indoles), and also represent a key regulatory pathway that mediates neuroinflammation [76]. Previous studies have shown that the activation of Microglia and AHR by host-derived ligands, represented by kynurenine, is detrimental after stroke, while the effects of post-stroke modification in AHR microbiota-derived ligands, by indoles, remain poorly understood [75]. However, AHR microbiota-derived ligands, such as indoles, are reduced in human plasma samples 24 h after ischemic stroke compared to controls, showing that post stroke GM changes could lead to a loss of microbially-derived indole-based ligands of AHR [76]. In particular, tryptophan could be metabolized to tryptamine in a TrpD-dependent manner by bacteria belonging to the *Clostridium*, *Ruminococcus*, *Blautia*, and *Lactobacillus* genera [77]. Furthermore, tryptophan can be metabolized by the GM into indole and its derivatives [78] by Gram-negative and Gram-positive bacterial species, including *Escherichia coli* and *Clostridium* spp. [79]. Consistently, very low levels of indole and skatole were detected in our IS patient cohort, which might be related both to the GM imbalance and the decreased abundance of Ruminococcaceae and Clostridiales (Clostridiaceae).

Certainly, the small cohort sample size may represent a study limitation, leading to a need for a further scaleup of patients to confirm these findings.

5. Conclusions

The results obtained from this study suggest a possible relationship between IS and GM modifications. Moreover, an altered GM composition could have indirect effects on the production of metabolites involved in important brain functions, such as SCFAs, from an increase in microbial SCFA producers. Herein, specific fecal signatures characterizing IS patients have been uncovered, such as a high abundance of acetic acid and *Akkermansia*, coupled with a low abundance of the Clostridiales order and Ruminococcaceae family, which could represent group of bacteria and metabolite typically associated to ischemic stroke.

Finally, this study on a limited adult Italian population may represent a pilot study for later investigations on GM of IS patients. It may play a pivotal role for future larger studies on adults and for new translating the issue to the IS pediatric disease.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/microorganisms12010037/s1>, Figure S1: LEfSe on L6 relative abundance and on the PICRUSt2 predicted pathways between IS_T₀ and CTRLs; Figure S2: Distribution of zonulin in IS patients T₀ and IS patients T₁; Figure S3: Pearson correlation analysis between ASVs, SCFAs and motricity index (MI_TOT); Table S1: Patients metadata; Table S2: Mean and *p*-value of differential expressed ASVs; Table S3: Metabolomics data; Table S4: Correlation between ASVs and BBP; Table S5: Correlation between SCFAs and Zonulin with BBP at T₁ time point.

Author Contributions: Conceptualization, R.M., C.M., P.V. and L.P.; methodology, R.M., C.M. and P.V.; validation, C.M. and M.S.; formal analysis, R.M., C.M., M.S., S.P., A.R. and P.V.; investigation, L.P., P.V., E.G. and F.M.; data curation, R.M., P.V., E.G. and F.M.; writing—original draft preparation, R.M., C.M. and P.V.; writing—review and editing, R.M., C.M., M.V., F.D.C. and P.V.; supervision, P.V., L.P. and F.M.; project administration, L.P. and F.M.; funding acquisition, L.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Italian Ministry of Health (Ricerca Corrente 2022, assigned to L.P.).

Informed Consent Statement: The study involving human participants was reviewed and approved by the Villa Beretta Ethics Committee for patients with ischemic stroke (protocol v.1.2 10/11/2020) and by the OPBG Ethics Committees for healthy subjects' (1404_OPBG_2017 and 1113_OPBG_2016) cohorts. Written informed consent has been obtained from all participants to publish this paper.

Data Availability Statement: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: PRJNA1030992, PRJNA996768, PRJNA531579 (<https://www.ncbi.nlm.nih.gov/bioproject>).

Acknowledgments: The Authors thanks Gabriele Macari and Ilaria Pirona for their contribution to the bioinformatics analyses; and Antonia Felicia Piazzesi for the English revision.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

CNS	Central nervous system
ANS	Autonomous nervous system
ENS	Enteric nervous system
GM	Gut microbiota
GI	Calibri
SCFAs	Short-chain fatty acids
BBP	Blood biochemical parameters
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
GGT	Gamma-glutamyl transpeptidase
CTRLs	Control subjects
IS	Ischemic stroke patients
BBT	Box and Block test
ARAT	Action Research Arm test
MI_TOT	Motricity Index test
10 MWT	10 Meter Walking test
OPBG	Bambino Gesù Children's Hospital
ASV	Amplicon Sequence Variant
GC	Gas chromatograph
MS	Mass spectrometer
NIST	National Institute of Standards and Technology
PCoA	Principal coordinate analyses
LEfSe	Linear discriminant analysis Effect Size
PICRUSt	Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
PLS-DA	Partial least-squares-discriminant analysis
LOQ	Limit of Quantification
IBS	Inflammatory bowel disease
CD	Coeliac disease
ASD	Autism spectrum disorder
AHR	Aryl hydrocarbon receptor
SPME	Solid-phase microextraction

References

1. Sudo, N.; Chida, Y.; Aiba, Y.; Sonoda, J.; Oyama, N.; Yu, X.; Kubo, C.; Koga, Y. Postnatal Microbial Colonization Programs the Hypothalamic–Pituitary–Adrenal System for Stress Response in Mice. *J. Physiol.* **2004**, *558*, 263–275. [[CrossRef](#)]

2. Zhang, Y.; Sharma, S.; Tom, L.; Liao, Y.-T.; Wu, V.C.H. Gut Phageome—An Insight into the Role and Impact of Gut Microbiome and Their Correlation with Mammal Health and Diseases. *Microorganisms* **2023**, *11*, 2454. [CrossRef]
3. Bonaz, B.; Bazin, T.; Pellissier, S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. *Front. Neurosci.* **2018**, *12*, 49. [CrossRef]
4. Bercik, P.; Collins, S.M.; Verdu, E.F. Microbes and the Gut-brain Axis. *Neurogastroenterol. Motil.* **2012**, *24*, 405–413. [CrossRef]
5. Li, X.; You, X.; Wang, C.; Li, X.; Sheng, Y.; Zhuang, P.; Zhang, Y. Bidirectional Brain-gut-microbiota Axis in Increased Intestinal Permeability Induced by Central Nervous System Injury. *CNS Neurosci. Ther.* **2020**, *26*, 783–790. [CrossRef]
6. Yarandi, S.S.; Peterson, D.A.; Treisman, G.J.; Moran, T.H.; Pasricha, P.J. Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. *J. Neurogastroenterol. Motil.* **2016**, *22*, 201–212. [CrossRef]
7. Heiss, C.N.; Olofsson, L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. *J. Neuroendocrinol.* **2019**, *31*, e12684. [CrossRef]
8. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.; Relman, D.A. Diversity of the Human Intestinal Microbial Flora. *Science* **2005**, *308*, 1635–1638. [CrossRef]
9. Natividad, J.M.M.; Verdu, E.F. Modulation of Intestinal Barrier by Intestinal Microbiota: Pathological and Therapeutic Implications. *Pharmacol. Res.* **2013**, *69*, 42–51. [CrossRef]
10. Fan, Y.; Pedersen, O. Gut Microbiota in Human Metabolic Health and Disease. *Nat. Rev. Microbiol.* **2021**, *19*, 55–71. [CrossRef]
11. Thursby, E.; Juge, N. Introduction to the Human Gut Microbiota. *Biochem. J.* **2017**, *474*, 1823–1836. [CrossRef] [PubMed]
12. Yamashiro, K.; Tanaka, R.; Urabe, T.; Ueno, Y.; Yamashiro, Y.; Nomoto, K.; Takahashi, T.; Tsuji, H.; Asahara, T.; Hattori, N. Gut Dysbiosis Is Associated with Metabolism and Systemic Inflammation in Patients with Ischemic Stroke. *PLoS ONE* **2017**, *12*, e0171521. [CrossRef]
13. Liu, M.; Wu, B.; Wang, W.-Z.; Lee, L.-M.; Zhang, S.-H.; Kong, L.-Z. Stroke in China: Epidemiology, Prevention, and Management Strategies. *Lancet Neurol.* **2007**, *6*, 456–464. [CrossRef] [PubMed]
14. Xia, G.-H.; You, C.; Gao, X.-X.; Zeng, X.-L.; Zhu, J.-J.; Xu, K.-Y.; Tan, C.-H.; Xu, R.-T.; Wu, Q.-H.; Zhou, H.-W.; et al. Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke. *Front. Neurol.* **2019**, *10*, 397. [CrossRef] [PubMed]
15. Durgan, D.J.; Lee, J.; McCullough, L.D.; Bryan, R.M. Examining the Role of the Microbiota-Gut-Brain Axis in Stroke. *Stroke* **2019**, *50*, 2270–2277. [CrossRef]
16. Spychala, M.S.; Venna, V.R.; Jandzinski, M.; Doran, S.J.; Durgan, D.J.; Ganesh, B.P.; Ajami, N.J.; Putluri, N.; Graf, J.; Bryan, R.M.; et al. Age-related Changes in the Gut Microbiota Influence Systemic Inflammation and Stroke Outcome. *Ann. Neurol.* **2018**, *84*, 23–36. [CrossRef]
17. Statler, K.D.; Dong, L.; Nielsen, D.M.; Bratton, S.L. Pediatric Stroke: Clinical Characteristics, Acute Care Utilization Patterns, and Mortality. *Childs Nerv. Syst.* **2011**, *27*, 565–573. [CrossRef]
18. Gardner, M.A.; Hills, N.K.; Sidney, S.; Johnston, S.C.; Fullerton, H.J. The 5-Year Direct Medical Cost of Neonatal and Childhood Stroke in a Population-Based Cohort. *Neurology* **2010**, *74*, 372–378. [CrossRef]
19. Geroin, C.; Mazzoleni, S.; Smania, N.; Gandolfi, M.; Bonaiuti, D.; Gasperini, G.; Sale, P.; Munari, D.; Waldner, A.; Spidalieri, R.; et al. Systematic Review of Outcome Measures of Walking Training Using Electromechanical and Robotic Devices in Patients with Stroke. *J. Rehabil. Med.* **2013**, *45*, 987–996. [CrossRef]
20. Mathiowetz, V.; Volland, G.; Kashman, N.; Weber, K. Adult Norms for the Box and Block Test of Manual Dexterity. *Am. J. Occup. Ther.* **1985**, *39*, 386–391. [CrossRef]
21. Lyle, R.C. A Performance Test for Assessment of Upper Limb Function in Physical Rehabilitation Treatment and Research. *Int. J. Rehabil. Res.* **1981**, *4*, 483–492. [CrossRef] [PubMed]
22. Wade, D.T. Measuring Arm Impairment and Disability after Stroke. *Int. Disabil. Stud.* **1989**, *11*, 89–92. [CrossRef] [PubMed]
23. Finch, E. *Physical Rehabilitation Outcome Measures: A Guide to Enhanced Clinical Decision Making*; Canadian Physiotherapy Association: Hamilton, ON, Canada, 2002; ISBN 978-1-55009-220-2.
24. Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F.; et al. Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2. *Nat. Biotechnol.* **2019**, *37*, 852–857. [CrossRef] [PubMed]
25. Zhao, G.; Nyman, M.; Åke Jönsson, J. Rapid Determination of Short-Chain Fatty Acids in Colonic Contents and Faeces of Humans and Rats by Acidified Water-Extraction and Direct-Injection Gas Chromatography. *Biomed. Chromatogr.* **2006**, *20*, 674–682. [CrossRef] [PubMed]
26. European Medicines Agency. ICH Guideline M10 on Bioanalytical Method Validation Step 2b. 2019. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf (accessed on 3 April 2022).
27. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM). Bioanalytical Method Validation—Guidance for Industry. 2018. Available online: <http://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf> (accessed on 3 April 2022).

28. Vernocchi, P.; Marini, F.; Capuani, G.; Tomassini, A.; Conta, G.; Del Chierico, F.; Malattia, C.; De Benedetti, F.; Martini, A.; Dallapiccola, B.; et al. Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. *Microorganisms* **2020**, *8*, 1540. [CrossRef] [PubMed]
29. Chen, J.; Bittinger, K.; Charlson, E.S.; Hoffmann, C.; Lewis, J.; Wu, G.D.; Collman, R.G.; Bushman, F.D.; Li, H. Associating Microbiome Composition with Environmental Covariates Using Generalized UniFrac Distances. *Bioinformatics* **2012**, *28*, 2106–2113. [CrossRef] [PubMed]
30. Welham, Z.; Déjean, S.; Lê Cao, K.-A. Multivariate Analysis with the R Package mixOmics. In *Statistical Analysis of Proteomic Data*; Burger, T., Ed.; Methods in Molecular Biology; Springer: New York, NY, USA, 2023; Volume 2426, pp. 333–359. ISBN 978-1-07-161966-7.
31. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **1995**, *57*, 289–300. [CrossRef]
32. Douglas, G.M.; Maffei, V.J.; Zaneveld, J.R.; Yurgel, S.N.; Brown, J.R.; Taylor, C.M.; Huttenhower, C.; Langille, M.G.I. PICRUSt2 for Prediction of Metagenome Functions. *Nat. Biotechnol.* **2020**, *38*, 685–688. [CrossRef]
33. Kanehisa, M.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M. KEGG as a Reference Resource for Gene and Protein Annotation. *Nucleic Acids Res.* **2016**, *44*, D457–D462. [CrossRef]
34. Kolde, R. Pheatmap: Pretty Heatmaps. Cran.R-Project. Available online: <https://cran.r-project.org/package=pheatmap> (accessed on 28 October 2019).
35. Wang, J.; Zhang, H.; He, J.; Xiong, X. The Role of the Gut Microbiota in the Development of Ischemic Stroke. *Front. Immunol.* **2022**, *13*, 845243. [CrossRef]
36. Honarpisheh, P.; Bryan, R.M.; McCullough, L.D. Aging Microbiota-Gut-Brain Axis in Stroke Risk and Outcome. *Circ. Res.* **2022**, *130*, 1112–1144. [CrossRef] [PubMed]
37. Hu, W.; Kong, X.; Wang, H.; Li, Y.; Luo, Y. Ischemic Stroke and Intestinal Flora: An Insight into Brain–Gut Axis. *Eur. J. Med. Res.* **2022**, *27*, 73. [CrossRef] [PubMed]
38. Bonnechère, B.; Amin, N.; Van Duijn, C. What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review. *Int. J. Mol. Sci.* **2022**, *23*, 13665. [CrossRef] [PubMed]
39. Stanley, D.; Moore, R.J.; Wong, C.H.Y. An Insight into Intestinal Mucosal Microbiota Disruption after Stroke. *Sci. Rep.* **2018**, *8*, 568. [CrossRef] [PubMed]
40. Suganya, K.; Koo, B.-S. Gut–Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. *Int. J. Mol. Sci.* **2020**, *21*, 7551. [CrossRef] [PubMed]
41. Rondanelli, M.; Gasparri, C.; Peroni, G.; Faliva, M.A.; Naso, M.; Perna, S.; Bazire, P.; Sajoux, I.; Maugeri, R.; Rigon, C. The Potential Roles of Very Low Calorie, Very Low Calorie Ketogenic Diets and Very Low Carbohydrate Diets on the Gut Microbiota Composition. *Front. Endocrinol.* **2021**, *12*, 662591. [CrossRef]
42. Kurowska, A.; Ziemichód, W.; Herbet, M.; Piątkowska-Chmiel, I. The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases. *Nutrients* **2023**, *15*, 1436. [CrossRef]
43. Chen, R.; Wu, P.; Cai, Z.; Fang, Y.; Zhou, H.; Lasanajak, Y.; Tang, L.; Ye, L.; Hou, C.; Zhao, J. Puerariae Lobatae Radix with Chuanxiong Rhizoma for Treatment of Cerebral Ischemic Stroke by Remodeling Gut Microbiota to Regulate the Brain–Gut Barriers. *J. Nutr. Biochem.* **2019**, *65*, 101–114. [CrossRef]
44. Liu, C.-Z.; Chen, W.; Wang, M.-X.; Wang, Y.; Chen, L.-Q.; Zhao, F.; Shi, Y.; Liu, H.-J.; Dou, X.-B.; Liu, C.; et al. *Dendrobium officinale* Kimura et Migo and American Ginseng Mixture: A Chinese Herbal Formulation for Gut Microbiota Modulation. *Chin. J. Nat. Med.* **2020**, *18*, 446–459. [CrossRef]
45. Gerhardt, S.; Mohajeri, M. Changes of Colonic Bacterial Composition in Parkinson’s Disease and Other Neurodegenerative Diseases. *Nutrients* **2018**, *10*, 708. [CrossRef]
46. López-Montoya, P.; Cerqueda-García, D.; Rodríguez-Flores, M.; López-Contreras, B.; Villamil-Ramírez, H.; Morán-Ramos, S.; Molina-Cruz, S.; Rivera-Paredes, B.; Antuna-Puente, B.; Velázquez-Cruz, R.; et al. Association of Gut Microbiota with Atherogenic Dyslipidemia, and Its Impact on Serum Lipid Levels after Bariatric Surgery. *Nutrients* **2022**, *14*, 3545. [CrossRef] [PubMed]
47. Goodrich, J.K.; Waters, J.L.; Poole, A.C.; Sutter, J.L.; Koren, O.; Blekhan, R.; Beaumont, M.; Van Treuren, W.; Knight, R.; Bell, J.T.; et al. Human Genetics Shape the Gut Microbiome. *Cell* **2014**, *159*, 789–799. [CrossRef] [PubMed]
48. Li, N.; Wang, X.; Sun, C.; Wu, X.; Lu, M.; Si, Y.; Ye, X.; Wang, T.; Yu, X.; Zhao, X.; et al. Change of Intestinal Microbiota in Cerebral Ischemic Stroke Patients. *BMC Microbiol.* **2019**, *19*, 191. [CrossRef] [PubMed]
49. Alamoudi, M.U.; Hosie, S.; Shindler, A.E.; Wood, J.L.; Franks, A.E.; Hill-Yardin, E.L. Comparing the Gut Microbiome in Autism and Preclinical Models: A Systematic Review. *Front. Cell. Infect. Microbiol.* **2022**, *12*, 905841. [CrossRef] [PubMed]
50. Vernocchi, P.; Ristori, M.V.; Guerrera, S.; Guarrasi, V.; Conte, F.; Russo, A.; Lupi, E.; Albitar-Nehme, S.; Gardini, S.; Paci, P.; et al. Gut Microbiota Ecology and Inferred Functions in Children With ASD Compared to Neurotypical Subjects. *Front. Microbiol.* **2022**, *13*, 871086. [CrossRef] [PubMed]
51. Taniya, M.A.; Chung, H.-J.; Al Mamun, A.; Alam, S.; Aziz, M.A.; Emon, N.U.; Islam, M.M.; Hong, S.-T.S.; Podder, B.R.; Ara Mimi, A.; et al. Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation. *Front. Cell. Infect. Microbiol.* **2022**, *12*, 915701. [CrossRef] [PubMed]

52. Ling, Z.; Jin, C.; Xie, T.; Cheng, Y.; Li, L.; Wu, N. Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population. *Sci. Rep.* **2016**, *6*, 30673. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Zhu, C.; Grandhi, R.; Patterson, T.; Nicholson, S. A Review of Traumatic Brain Injury and the Gut Microbiome: Insights into Novel Mechanisms of Secondary Brain Injury and Promising Targets for Neuroprotection. *Brain Sci.* **2018**, *8*, 113. [\[CrossRef\]](#)
54. Zhang, N.; Wang, H.; Wang, X.; Tian, M.; Tian, Y.; Li, Q.; Liang, C.; Peng, X.; Ding, J.; Wu, X.; et al. Combination Effect between Gut Microbiota and Traditional Potentially Modifiable Risk Factors for First-Ever Ischemic Stroke in Tujia, Miao and Han Populations in China. *Front. Mol. Neurosci.* **2022**, *15*, 922399. [\[CrossRef\]](#)
55. Sun, H.; Gu, M.; Li, Z.; Chen, X.; Zhou, J. Gut Microbiota Dysbiosis in Acute Ischemic Stroke Associated With 3-Month Unfavorable Outcome. *Front. Neurol.* **2022**, *12*, 799222. [\[CrossRef\]](#)
56. Li, A.; Yang, Y.; Qin, S.; Lv, S.; Jin, T.; Li, K.; Han, Z.; Li, Y. Microbiome Analysis Reveals Gut Microbiota Alteration of Early-Weaned Yimeng Black Goats with the Effect of Milk Replacer and Age. *Microb. Cell Fact.* **2021**, *20*, 78. [\[CrossRef\]](#) [\[PubMed\]](#)
57. Lee, Y.T.; Mohd Ismail, N.I.; Wei, L.K. Microbiome and Ischemic Stroke: A Systematic Review. *PLoS ONE* **2021**, *16*, e0245038. [\[CrossRef\]](#) [\[PubMed\]](#)
58. Jia, J.; Zhang, H.; Liang, X.; Dai, Y.; Liu, L.; Tan, K.; Ma, R.; Luo, J.; Ding, Y.; Ke, C. Correction to: Application of Metabolomics to the Discovery of Biomarkers for Ischemic Stroke in the Murine Model: A Comparison with the Clinical Results. *Mol. Neurobiol.* **2022**, *59*, 2657. [\[CrossRef\]](#) [\[PubMed\]](#)
59. Sadler, R.; Cramer, J.V.; Heindl, S.; Kostidis, S.; Betz, D.; Zuurbier, K.R.; Northoff, B.H.; Heijink, M.; Goldberg, M.P.; Plautz, E.J.; et al. Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological Mechanisms. *J. Neurosci.* **2020**, *40*, 1162–1173. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Ke, X.; Xiang, Q.; Jiang, P.; Liu, W.; Yang, M.; Yang, Y.; Shi, D.; Chen, L.; Tao, J. Effect of Electroacupuncture on Short-Chain Fatty Acids in Peripheral Blood after Middle Cerebral Artery Occlusion/Reperfusion in Rats Based on Gas Chromatography–Mass Spectrometry. *Mediat. Inflamm.* **2022**, *2022*, 3997947. [\[CrossRef\]](#) [\[PubMed\]](#)
61. Oleskin, A.V.; Shenderov, B.A. Neuromodulatory Effects and Targets of the SCFAs and Gasotransmitters Produced by the Human Symbiotic Microbiota. *Microb. Ecol. Health Dis.* **2016**, *27*, 30971. [\[CrossRef\]](#) [\[PubMed\]](#)
62. Vinolo, M.A.R.; Rodrigues, H.G.; Nachbar, R.T.; Curi, R. Regulation of Inflammation by Short Chain Fatty Acids. *Nutrients* **2011**, *3*, 858–876. [\[CrossRef\]](#)
63. Singh, V.; Roth, S.; Llovera, G.; Sadler, R.; Garzetti, D.; Stecher, B.; Dichgans, M.; Liesz, A. Microbiota Dysbiosis Controls the Neuroinflammatory Response after Stroke. *J. Neurosci.* **2016**, *36*, 7428–7440. [\[CrossRef\]](#)
64. Xu, K.; Gao, X.; Xia, G.; Chen, M.; Zeng, N.; Wang, S.; You, C.; Tian, X.; Di, H.; Tang, W.; et al. Rapid Gut Dysbiosis Induced by Stroke Exacerbates Brain Infarction in Turn. *Gut* **2021**, *70*, 1486–1494. [\[CrossRef\]](#)
65. Macfarlane, S.; Macfarlane, G.T. Regulation of Short-Chain Fatty Acid Production. *Proc. Nutr. Soc.* **2003**, *62*, 67–72. [\[CrossRef\]](#)
66. Salazar, N.; Arbolea, S.; Fernández-Navarro, T.; De Los Reyes-Gavilán, C.G.; Gonzalez, S.; Gueimonde, M. Age-Associated Changes in Gut Microbiota and Dietary Components Related with the Immune System in Adulthood and Old Age: A Cross-Sectional Study. *Nutrients* **2019**, *11*, 1765. [\[CrossRef\]](#) [\[PubMed\]](#)
67. Lee, J.; d'Aigle, J.; Atadja, L.; Quaiocoe, V.; Honarpisheh, P.; Ganesh, B.P.; Hassan, A.; Graf, J.; Petrosino, J.; Putluri, N.; et al. Gut Microbiota–Derived Short-Chain Fatty Acids Promote Poststroke Recovery in Aged Mice. *Circ. Res.* **2020**, *127*, 453–465. [\[CrossRef\]](#) [\[PubMed\]](#)
68. Henry, N.; Frank, J.; McLouth, C.; Trout, A.L.; Morris, A.; Chen, J.; Stowe, A.M.; Fraser, J.F.; Pennypacker, K. Short Chain Fatty Acids Taken at Time of Thrombectomy in Acute Ischemic Stroke Patients Are Independent of Stroke Severity But Associated With Inflammatory Markers and Worse Symptoms at Discharge. *Front. Immunol.* **2022**, *12*, 797302. [\[CrossRef\]](#) [\[PubMed\]](#)
69. Dang, Y.; Zhang, X.; Zheng, Y.; Yu, B.; Pan, D.; Jiang, X.; Yan, C.; Yu, Q.; Lu, X. Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study. *Neural Plast.* **2021**, *2021*, 1469339. [\[CrossRef\]](#) [\[PubMed\]](#)
70. Olsen, A.B.; Hetz, R.A.; Xue, H.; Aroom, K.R.; Bhattarai, D.; Johnson, E.; Bedi, S.; Cox, C.S.; Uray, K. Effects of Traumatic Brain Injury on Intestinal Contractility. *Neurogastroenterol. Motil.* **2013**, *25*, 593–e463. [\[CrossRef\]](#) [\[PubMed\]](#)
71. Fasano, A. All Disease Begins in the (Leaky) Gut: Role of Zonulin-Mediated Gut Permeability in the Pathogenesis of Some Chronic Inflammatory Diseases. *F1000Res* **2020**, *9*, 69. [\[CrossRef\]](#) [\[PubMed\]](#)
72. Xu, Y.; Wang, Y.; Li, H.; Dai, Y.; Chen, D.; Wang, M.; Jiang, X.; Huang, Z.; Yu, H.; Huang, J.; et al. Altered Fecal Microbiota Composition in Older Adults With Frailty. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 696186. [\[CrossRef\]](#) [\[PubMed\]](#)
73. Zheng, Q.; Chen, Y.; Zhai, Y.; Meng, L.; Liu, H.; Tian, H.; Feng, R.; Wang, J.; Zhang, R.; Sun, K.; et al. Gut Dysbiosis Is Associated With the Severity of Cryptogenic Stroke and Enhanced Systemic Inflammatory Response. *Front. Immunol.* **2022**, *13*, 836820. [\[CrossRef\]](#)
74. Roth, W.; Zadeh, K.; Vekariya, R.; Ge, Y.; Mohamadzaheh, M. Tryptophan Metabolism and Gut-Brain Homeostasis. *Int. J. Mol. Sci.* **2021**, *22*, 2973. [\[CrossRef\]](#)
75. Xie, Y.; Zou, X.; Han, J.; Zhang, Z.; Feng, Z.; Ouyang, Q.; Hua, S.; Liu, Z.; Li, C.; Cai, Y.; et al. Indole-3-Propionic Acid Alleviates Ischemic Brain Injury in a Mouse Middle Cerebral Artery Occlusion Model. *Exp. Neurol.* **2022**, *353*, 114081. [\[CrossRef\]](#)
76. Ganesh, B.P.; Peesh, P.; Blasco, M.P.; Hamamy, A.E.; Khan, R.; Guzman, G.; Honarpisheh, P.; Mohan, E.C.; Goodman, G.W.; Nguyen, J.N.; et al. Restoring a Balanced Pool of Host-Derived and Microbiota-Derived Ligands of the Aryl Hydrocarbon Receptor Is Beneficial after Stroke. *Res. Sq.* **2023**, in press. [\[CrossRef\]](#)

-
77. Williams, B.B.; Van Benschoten, A.H.; Cimerancic, P.; Donia, M.S.; Zimmermann, M.; Taketani, M.; Ishihara, A.; Kashyap, P.C.; Fraser, J.S.; Fischbach, M.A. Discovery and Characterization of Gut Microbiota Decarboxylases That Can Produce the Neurotransmitter Tryptamine. *Cell Host Microbe* **2014**, *16*, 495–503. [[CrossRef](#)] [[PubMed](#)]
 78. Agus, A.; Planchais, J.; Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. *Cell Host Microbe* **2018**, *23*, 716–724. [[CrossRef](#)] [[PubMed](#)]
 79. Lee, J.-H.; Lee, J. Indole as an Intercellular Signal in Microbial Communities. *FEMS Microbiol. Rev.* **2010**, *34*, 426–444. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.